© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Gabapentin changed neuropathic pain management. After its introduction, researchers quickly realized there’s a tangled family of related compounds—each byproduct tells a story. Compound D sits in that group, often mentioned in analytical labs and regulatory documents. Those tracking pharmaceutical purity watch it closely, not only as a benchmark for manufacturing quality. Tracing Compound D’s path from an obscure byproduct to a monitored substance shows how deeply safety and precision matter in modern pharmaceuticals. Chemists never overlook a “minor” compound, and for good reason. A “minor” presence sometimes hints at process drifts, aging, or stability shortcomings. Growing attention to substances like Gabapentin Related Compound D came as regulators pushed for higher standards and finer detection tools enabled more precise breakdowns of finished drugs.
The makeup of Compound D isn’t just textbook chemistry—it affects storage, handling, and even how pharmacies dispense medications. Its solubility, stability in air or light, and melting point sit front-and-center during manufacturing audits. Labs don’t just look for whether Compound D pops up but measure how much, and in which conditions it spikes. In personal experience working in scientific publishing, major journals reject research unless analytical data addresses all listed impurities, including Compound D. Knowing the spectral fingerprints, reactivity, and breakdown pathways isn’t just for academic satisfaction: it keeps patients safe from unseen risks, while giving confidence to regulators and drug makers alike. Labeling rules reflect the pressure to tell the truth—not just marketing gloss—before medicine reaches a shelf. If levels creep above accepted norms, that batch rarely leaves the factory.
Origin stories in chemistry rarely sound clean. Compound D doesn’t show up by accident or intent; it surfaces when certain preparation routes veer off by a fraction. Some synthetic routes for gabapentin trip over this byproduct when reaction times go long, or temperatures creep. Pharmacists who trained in the 90s remember the struggle to weed out unwanted compounds using clunky techniques. Now, advanced chromatography and mass spectrometry let teams spot even the faintest Compound D shadow. In my time on editorial boards, reviewers grilled authors about their handling of these modifications and degradants because even a fraction of a percent can matter during chronic dosing. After all, science cares less about what usually works and more about what might go wrong for someone vulnerable.
In regulatory speak and journal articles alike, synonyms stack up. Compound D sometimes masquerades behind registry numbers or systematic IUPAC phrases, but pharmacies, toxicologists, and researchers agree on a common language for clarity. The world of pharmaceutical regulations thrives on precision, but confusion often reigns when paperwork from different countries uses divergent labels for the same chemical. Auditors and pharmacists fight mix-ups every day because one wrong synonym in a batch record can mean product recalls and international headaches. A consistent name isn’t about bureaucracy—it’s how everyone from chemists to frontline clinicians can trust they’re talking about the same entity, sidestepping mistakes in translation, paperwork, or pharmacy software.
Compound D’s reputation owes less to what it does in the body and more to what it reveals. Most current research sees it as a “marker” impurity—a canary signaling where a process tilts out of balance. Its safety profile hasn’t triggered the alarm bells of some notorious contaminants, but the volume of scrutiny isn’t wasted. Several large incidents over the last two decades, involving completely unrelated drugs, shook public trust because ignored impurities led to recalls. Compound D doesn’t seem toxic at trace levels according to available studies, yet the pressure never lets up—because what isn’t measured now could become tomorrow’s health story. Precision, vigilance, and data transparency have become a way of life, not a box-checking exercise.
In daily pharmaceutical production, the search for impurities like Compound D drives engineers and chemists to push processes towards cleaner, safer, more predictable outcomes. Modern plants run advanced quality checks to catch even faint signals in vast batches. This isn’t just about regulatory peace of mind; it’s about people who take gabapentin daily and trust their medication won’t deliver surprises. In the research labs I’ve visited, teams constantly run stability studies, accelerating “aging” conditions to see if Compound D emerges over months or years. These efforts keep recalls low and patient safety high. The lessons learned from tracking Compound D bleed into broader GMP (Good Manufacturing Practice) culture, raising standards across facilities and even shaping training for new staff.
The future of monitoring Gabapentin Compound D sits at the intersection of better analytical technology and heightened public expectations. Automated chromatographic systems grow even more sensitive, laying bare process ghosts older teams could only guess at. The pressure for full data transparency grows. In drug development pipelines, companies now run forced degradation studies as early as possible, analyzing not just active molecules but their less-loved siblings—including Compound D. Toxicity research will never rest, even if all signs point to negligible risk for now. If new synthetic routes or storage packaging ever ramp up trace levels, data from today’s detailed analytical work will cut through panic, guiding quick decisions.
Continuous improvement counts most in this field. Pharmaceutical innovators experiment with green chemistry and better catalysts not for PR but because every streamlined step means less chance for byproducts like Compound D to crop up. Global regulators and industry watchdogs foster open databases making impurity tracking less of a guessing game. Cross-border harmonization still has ground to cover, but consensus on impurity thresholds and safety testing beats back confusion. In my own circles, collaboration between academic labs and industry partners speeds up findings—insight into one minor impurity often sparks cleaner processes for dozens more. All this circles back to the reason for such vigilance: patients expecting safe, effective medicines, unsullied by tiny, hidden leftovers from the lab.
Gabapentin, as many people know, has changed the way nerve pain and some types of seizures are managed. Most don’t realize that medications like gabapentin don’t come out of a single clean chemical process. Instead, manufacturing leaves behind traces of related compounds. Gabapentin Related Compound D is one of those trace chemicals, a byproduct or impurity that forms during production. Chemically, it’s close to gabapentin itself, but the slight differences matter.
Drug manufacturers pay serious attention to these related compounds. Even tiny amounts can raise red flags with health regulators. I’ve seen researchers pore over analytic printouts, trying to figure out how even slight impurities could change how a drug behaves or how safe it stays over time. The FDA and other agencies demand documentation and tight control over such compounds, because their effects aren’t always well understood. Unlike the main drug, little research goes into these byproducts—so they stick to strict limits.
It’s easy to dismiss talk about impurities as something only scientists or regulators worry about. Yet, this detail flows right down to real-world safety. Imagine a batch of capsules with too much of a related compound like Compound D. That could accidentally change how a medication works or even bunk the stability, giving some people unexpected side effects. During my time around pharmacists, I heard about recalls triggered by stuff like this—an extra percentage point somewhere in a lab test, and everything gets pulled back or tossed out.
Companies disclose levels of these byproducts on certificates of analysis for every batch. Pharmacists and doctors rarely dig into the chemistry, but the oversight from the FDA and similar organizations acts as the safety net. Every time something new pops up in the research, companies face new questions—does this unknown chemical build up in the body, does it mess with organ systems, does it even have its own biologic activity? Regulators lean toward caution because history shows what can happen if these tiny details get ignored.
Making a pure, safe drug is far from straightforward. Even with lots of quality checks, chemistry has a way of slipping in surprises. Bringing those trace amounts down takes new purification technologies, constant batch testing, and sometimes even reworking the main manufacturing process. Years ago, a chemist told me about tweaking temperatures, swapping solvents, testing and retesting to get Compound D down to parts per million. It’s a never-ending cycle of improvement and investment.
Regulators put limits in place for a reason: keep risks as close to zero as possible for patients. The pharmaceutical industry slowly adapts, sometimes dragging its feet due to cost or technical hurdles. Open scientific dialogue could help—more shared studies on these little-known compounds, faster identification of possible risks, stricter but fair rules agreed across borders. Transparency helps too. Publishing impurity data makes regulators, doctors, and even patients safer. The public has a right to trust what goes in each pill, and that starts with sweating the small stuff—even if it’s something most never hear about, like Gabapentin Related Compound D.
Most people might recognize the name gabapentin because of its widespread use for nerve pain or seizures. In labs and manufacturing, scientists keep a sharp eye on more than just the main molecule. Gabapentin Related Compound D is one of those extra substances—the kind that matters a lot in pharmaceutical research, even though you won’t see it on prescription labels at the pharmacy.
I’ve talked to people in drug manufacturing who always bring up related compounds when the topic turns to safety. It’s all about knowing exactly what's in each pill or capsule. Gabapentin Related Compound D comes up during purity checks. If the drug contains too much of this or other related compounds, something has gone wrong in the process. Regulators like the FDA expect labs to spot even tiny amounts.
I remember reading how high-performance liquid chromatography (HPLC) machines are tuned to catch compounds like this one. Technicians look for specific peaks in data that say Compound D is present. This isn’t just showing off technical muscle. Pharmaceutical companies track these molecules for patient safety. Extra substances could mean impurities, which sometimes trigger side effects or show manufacturing controls slipping.
I’ve sat in on meetings where analysts talk about “limits of detection” and “threshold values.” The conversation always turns practical: how much Compound D can sneak in before the product fails quality checks? International rules, like those set by the International Council for Harmonisation (ICH), draw these lines. Regulators want to see hard numbers and clear proof that companies can spot and measure impurities accurately—even down to parts per million.
Labs prepare standard solutions containing gabapentin and a measured amount of Related Compound D. They run these on their systems to calibrate their machines. If the process in the factory changes, the ratio of these compounds can shift. By keeping a close watch, companies can find and fix problems with raw materials or production equipment before these compounds build up to troubling levels.
People might think pharmaceutical science only worries about the active ingredient, but that doesn't tell the whole story. Every bottle of gabapentin has been cleared through a maze of checks, many of which focus on things like Related Compound D. When regulators and auditors show up for inspections, their files fill up with records on these so-called minor molecules. Each number and chemical trace helps prove the product on the shelf is both safe and consistent from batch to batch.
One risk if companies cut corners or testing falters: patients could end up getting side effects or lower effectiveness from that bottle of pills. In my experience, everyone in this business wants customers to trust their medicine. Testing for things like Gabapentin Related Compound D isn't an extra step—it's the assurance that the drug meets the mark every time.
There's always a push to tighten standards as manufacturing gets more complex and global. Automated testing, stricter documentation, and even artificial intelligence help labs catch rare issues before they snowball into bigger problems. Investment in these areas pays off, not just in profit or avoided recalls, but in keeping patients’ trust.
Gabapentin Related Compound D offers a behind-the-scenes lesson: The quiet details often matter most. Keeping track of these lesser-known molecules, labs protect public health on a level that most people never see.
Gabapentin Related Compound D doesn’t land on anyone’s list of household names. Most people outside the pharmaceutical world have never heard of it. This compound comes up during drug production and quality control for gabapentin—better known to patients for nerve pain and seizures. Many regulatory agencies watch closely for how much of this compound shows up, since impurities or byproducts can affect how safe a medication really is. Rigorous control over Gabapentin Related Compound D is not just red tape; it matters for real-world patient safety.
Gabapentin Related Compound D acts a bit like food that spoils if left on a sunny countertop. Moisture, heat, and bright light speed up its degradation. That’s not just theoretical. Studies show temperature swings or humidity above 60% increase the risk of decomposition, possibly altering active drug levels or creating unsafe byproducts. At the company where I cut my teeth in pharma, quality inspectors spent as much time monitoring environment controls as running batch tests. Clean, climate-controlled storage stopped small issues from growing into recalls or failed batches.
Direct sunlight never gets a glance at this compound. Pharmaceutical teams will put it in tight containers, with airtight seals, far from any windows. Ordinary plastic won’t cut it; pharmaceutical-grade glass or HDPE blocks moisture. Some labs even fill storage spaces with inert gases, like nitrogen, to shield contents from both air and any sneaky traces of water vapor. Avoiding fluctuations in temperature tops the list: 20 to 25°C stays safest, since cold or excessively warm storerooms both stress the compound’s stability. This temperature range matches most active pharmaceutical ingredients, based on extensive FDA and EMA guidelines, and lines up with many years’ worth of audit reports from the inspections I’ve witnessed.
Slip-ups during handling account for half the surprises in a lab notebook. Anyone who transfers Gabapentin Related Compound D wears protective gloves—nobody wants a chemical burn or contamination. Most facilities set up special workspaces with laminar flow hoods, just to keep airborne particles to a minimum. Spills get cleaned up quickly and never simply wiped into a drain. Every gram counts, so traceability matters: logging lot numbers, amounts, and storage conditions stops confusion if there’s ever a question months down the line. Skipping any of those steps usually led, in my experience, to embarrassing calls from auditors.
It’s tempting to overlook these backstage choices, yet every time a patient takes gabapentin, those controls play a role. Keeping impurities like Gabapentin Related Compound D in check helps avoid hidden risks. Regulators including the FDA, EMA, and ICH press for tough standards for a reason: past incidents involving poorly stored compounds have ended in recalls and, occasionally, patient harm. Since gabapentin remains one of the most prescribed medications globally, sloppiness in handling related compounds could have impact far beyond a single lab.
Standardizing training helps. At my previous job, consistent refreshers on safe handling and clear, posted protocols reduced mistakes. Investing in smarter storage solutions—like humidity alarms and automatic logs—keeps issues from flying under the radar. Sharing lessons from past slip-ups cultivates awareness that keeps teams sharp. While the manual work can feel repetitive, its payoff is measured in the medicine cabinets and the well-being of millions of patients. Accountability, not just compliance, proves the difference between routine safety and expensive recalls.
Gabapentin has become a staple in both neurology offices and chronic pain clinics. It’s popular for nerve pain, seizures, and sometimes off-label uses. When you look into testing and standards, you bump into something called “related compounds.” These usually show up as expected byproducts or impurities during manufacturing. Gabapentin Related Compound D sits on the list. Analytical chemists keep an eye out for it because it helps ensure the final product stays safe and trustworthy.
Suppose a pharma company or an independent tester needs pure Gabapentin Related Compound D for comparison or quality control. The first thing buyers ask is if suppliers can provide a certificate of analysis (COA). This certificate proves the compound has been independently tested and matches the required purity and identity. Without a COA, you only have a mystery powder. Labs, doctors, and pharmacies do not mess around when it comes to unknowns, especially with regulatory audits looming.
Manufacturers and labs with a good track record tend to work above board and only release chemical reference materials with a fresh COA. Reputable chemical companies—think Sigma-Aldrich, USP, or LGC—make sure every bottle ships alongside paperwork showing tests for purity, moisture, and other critical details. In my years helping R&D teams, nobody trusted a sample unless the COA looked genuine and up-to-date. When projects hit snags, it often traced back to skipping this paperwork or trusting a dubious source.
Pricing, paperwork, and approvals all matter. Not every country treats these reference standards the same way; some enforce stricter import rules or keep tight controls on lab usage. Sometimes gray-market suppliers promise to ship Gabapentin Related Compound D without a COA or attach a generic printout. It's tempting if you're in a hurry or budgets are tight. Skipping official channels can haunt you—projects stall, results get thrown out, and regulators may start digging into all your records.
Beyond paperwork, there's safety. These impurities might seem harmless in trace amounts, but without a lab-verified sample, nobody knows what else came along for the ride. I've seen confusion and costly rework unfold when teams took a shortcut. For regulated clinical studies and commercial drug production, a COA-backed reference isn’t just best practice—it’s the rule.
Serious buyers typically turn to suppliers accredited by ISO guidelines, which guarantees both the paperwork and the substance inside. Many suppliers let you download sample COAs directly from their sites or offer authentication on request. Always talk to technical support before sending a purchase order. A real expert will explain the certification process, expiration timelines, and the shipping logistics—sometimes even legal hoops if controlled substances are involved.
If a supplier dodges questions or fails to provide actual test data for Gabapentin Related Compound D, treat it as a red flag. Scientists and compliance officers know that documentation protects teams, patients, and the company’s reputation. Rushed decisions often lead to bigger headaches down the line.
Building a list of trusted suppliers pays off. A quick call to peers or a scan through regulatory bulletins usually turns up names you can count on. Auditing suppliers once a year helps weed out bad actors or outdated practices. Research teams share COAs with regulatory filings and sometimes even with clients, using these documents as an extra layer of proof. Real transparency keeps both science and business running smoothly.
Gabapentin Related Compound D usually comes up in pharmaceutical quality control conversations. Its chemical name is 1,1-cyclohexaneacetic acid, which tells a lot about its core structure. The molecular formula is C8H14O2. Visualizing that, the compound centers around a cyclohexane ring—a six-carbon structure, each carbon linked as a repeating hexagon, quite stable and common in organic chemistry. Attached to this ring is an acetic acid side chain. So, the skeleton features the cyclohexane (C6H11) with a two-carbon acetic acid group (CH2COOH) hanging off one position. The systematic arrangement signals why it sometimes emerges as an impurity in synthesizing gabapentin, which shares this cyclohexane framework.
Anyone who spends time in pharmaceutical labs will recognize how vital it is to watch for related compounds, especially during synthesis. Manufacturers of gabapentin want products with minimum contamination. Compound D forms as a by-product, so strict guidelines set limits on its allowable concentration. Regulatory agencies like the FDA don't leave much to chance. Mitigating impurities ensures patient safety, keeps side effects predictable, and maintains medication reliability. The industry standard points to less than 0.1% of Related Compound D in finished gabapentin tablets and capsules. Staying within these bounds means that manufacturers need highly sensitive analytical methods, like HPLC, to detect even faint traces.
Every batch release involves deep analysis for impurities. It becomes easy to overlook how simple chemicals like Related Compound D can affect real-world patients. Though not known as a toxic substance on its own, anything outside the intended active ingredient profile could spark allergic reactions or interact unpredictably with other drugs. General experience in production labs teaches the value of consistency—outlier batches often signal trouble with solvent quality, reaction temperatures, or raw material source. These small changes can tip the balance, raising impurity levels. This means recordkeeping and ongoing process tweaks are ordinary but essential.
Technical teams have learned a lot from repeated process reviews. Adjusting reaction temperatures during synthesis, sourcing higher-grade cyclohexanone or ensuring acidity stays within range can shave down impurity levels. Switching to catalysts that selectively guide reactions also helps, reducing formation of by-products like Compound D. On the analytical front, using methods with higher sensitivity and selectivity catches problems before they escalate. The human side matters too—continuous staff training ensures those minor process slips don’t go unnoticed. In modern pharmaceutical lines, cross-disciplinary teams discuss every deviation to find the root cause, then share learnings so future batches see fewer surprises.
Understanding the chemical structure and implications of Gabapentin Related Compound D isn't just about naming another impurity. It links chemistry, safety, and practical know-how. By reducing its presence, quality improves and patients gain added confidence in their medications—something every person, patient or professional, can appreciate.
| Names | |
| Preferred IUPAC name | 2-(2-aminopropyl)pentanoic acid |
| Other names |
2-(1-Isopropylaminoethyl)hexanoic acid 1-Isopropylaminoethyl)hexanoic acid URSODEOXYCHOLIC ACID EP IMPURITY B |
| Pronunciation | /ˌɡæbəˈpɛntɪn rɪˈleɪtɪd ˈkɒmpaʊnd diː/ |
| Identifiers | |
| CAS Number | 60946-18-3 |
| 3D model (JSmol) | `load =C1=CC(=CC=C1C(=O)O)CN` |
| Beilstein Reference | 152875 |
| ChEBI | CHEBI:142404 |
| ChEMBL | CHEMBL1536 |
| ChemSpider | 13936977 |
| DrugBank | DB00996 |
| ECHA InfoCard | ECHA InfoCard: 100.125.097 |
| EC Number | EC 232-135-5 |
| Gmelin Reference | 1286038 |
| KEGG | C08664 |
| MeSH | D09.468.569.010.500.437.187.250 |
| PubChem CID | 122163 |
| RTECS number | VH1200000 |
| UNII | 190R5FD7FQ |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID30884252 |
| Properties | |
| Chemical formula | C10H15NO2 |
| Molar mass | 171.24 |
| Appearance | White or off-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Sparingly soluble in water |
| log P | 0.62 |
| Acidity (pKa) | 3.68 |
| Basicity (pKb) | 2.7 |
| Dipole moment | 3.04 D |
| Pharmacology | |
| ATC code | N03AX12 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. |
| GHS labelling | GHS07; Warning; H302, H315, H319 |
| Pictograms | `[GHS07][GHS08]` |
| Signal word | Warning |
| Hazard statements | No Hazardous Statement. |
| Precautionary statements | Precautionary statements: P261, P264, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P312, P332+P313, P337+P313, P362+P364 |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| Flash point | 91.9°C |
| LD50 (median dose) | LD50 (median dose): 3200 mg/kg (Rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | Not more than 0.15% |
| Related compounds | |
| Related compounds |
Gabapentin Gabapentin lactam Gabapentin Related Compound A Gabapentin Related Compound B Gabapentin Related Compound C |
